In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) study, the incidence of cardiovascular disease was lower when liraglutide was used in patients with type 2 diabetes [15]

Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network Open (2022) Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system, Frontiers in Public Health (2022) Once-weekly semaglutide in adults with overweight or obesity, The New England Journal of Medicine (2021) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity, and Metabolism (2022) TOzempic diet plan: Foods to eat & avoid while taking Ozempic, Nourish (2023) Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs), StatPearls (2024) Ozempic for weight loss: Does it work, and what do experts recommend?, UC Davis Health (2023) What is Ozempic?, Novo Nordisk (2023) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

While the base compounds are FDA-approved drugs, compounded formulations are not FDA-approvedthey are manufactured to USP standards under state pharmacy board oversight for individual patient use
If youre in Louisiana, youll need to look at other providers
Wegovy had the same issues during this stage of its trial, and adverse medical effects such as gastroparesis or bowel obstruction were never included on the warning label